UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in our charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement
On May 4, 2022, the Company and the holder of all of the Company’s Series A Preferred Stock (the “Investor”), entered into a Forbearance Agreement and Waiver, dated April 27, 2022, wherein the Investor confirmed that no Triggering Event as defined under the Certificate of Designations for the Series A Preferred Stock (“COD”) has occurred prior to April 27, 2022, that a Triggering Event under Section 5(a)(ii) will and has occurred on April 29, 2022, and that in consideration for the Registration Delay Payments the Company is obligated to pay under the Registration Rights Agreement dated May 20, 2021 (“RRA”), and additional amounts the Company is obligated to pay under the COD and the Investor’s legal fees incurred in the preparation of the Forbearance Agreement and Waiver in the aggregate of $538,823.00 to be paid upon execution of the Forbearance Agreement and Waiver, and so long as the Company pays the Registration Delay Payments that become due and payable under the RRA after the execution of the Forbearance Agreement and Waiver, the Investor has agreed to forbear exercising any rights or remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a)(ii) of the COD and Section 4(c)(ii) of the Warrant until the earlier to occur of (i) the date immediately prior to the date of occurrence of a Bankruptcy Triggering Event, (ii) the date of occurrence of any other Triggering Event under Section 5(a) of the COD (excluding any Triggering Event arising solely as a result of Section 5(a)(ii) of the COD and Section 4(c)(ii) of the Warrant), (iii) the time of any breach by the Company under the Forbearance Agreement and Waiver, (iv) the Resale Availability Date as defined therein and (v) June 4, 2022 (such period, the “Forbearance Period”). Provided that the Company is not in breach of its obligations under Forbearance Agreement and Waiver, effective as of the Trading Day immediately following the date the Company cures the Triggering Event under Section 5(a)(ii) of the COD, the Investor agrees to waive any rights or remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a) of the COD and Section 4(c)(ii) of the Warrant that may have arisen prior to the date of the Forbearance Agreement and Waiver. The COD and RRA were previously filed as Exhibits 3.4 and 10.9 to the Company’s Registration Statement on Form S-1 initially filed with the Securities and Exchange Commission on September 13, 2021, as amended.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit | Exhibit Description | |
| 10.1 | Forbearance Agreement and Waiver | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized.
| Allarity Therapeutics, Inc. | ||
| By: | /s/ Steve Carchedi | |
| Steve Carchedi | ||
| Chief Executive Officer | ||
| Dated: May 5, 2022 | ||
Exhibit 10.1
FORBEARANCE AGREEMENT AND WAIVER
This Forbearance Agreement and Waiver (the “Agreement”), dated April 27, 2022, is by and between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and 3i, LP, a Delaware limited partnership (the “Investor”). In this Agreement, the Company and the Investor may each be referred to individually as a “Party” and collectively as the “Parties.” Unless otherwise defined in this Agreement, capitalized terms have the same meaning as defined in the Company’s Certificate of Designations (“COD”) for the Company’s Series A Preferred Stock or the Securities Purchase Agreement (“SPA”) and Registration Rights Agreement (“RRA”) each executed by the Parties on May 20, 2022, as amended.
RECITALS
| A. | Prior to the date of this Agreement, the Parties entered into the SPA and RRA, as amended, pursuant to which the Investor acquired certain Preferred Shares and Warrants from the Company on December 20, 2021. |
| B. | A registration statement on Form S-1 registering the resale of the Conversion Shares and the Warrant Shares (the “Registration Statement”) was declared effective by the SEC on December 20, 2021. As of the date of this Agreement, the Investor is the holder of all of the issued and outstanding Preferred Shares and Warrants. |
| C. | On April 12, 2022, the Company provided notice to the Investor under Section 3(r) of the RRA that there existed material non-public information that would require a post-effective amendment to the Registration Statement commencing an Allowable Grace Period under the RRA that expired on April 22, 2022. On April 25, 2022, notice was given by the Company to the Investor under Section 3(f) of the RRA that the Company intended to file a post-effective amendment to the Registration Statement on or before April 29, 2022, that would include restated audited financial statements for the year ended December 31, 2020, and new audited financial statements for the year ended December 31, 2021. |
| D. | With the passage of time, a Triggering Event under Section 5(a)(ii) of the COD will occur on April 29, 2022, as a result of the Registration Statement and its Prospectus contained therein not being available to the Investor for the resale of the Conversion Shares and the Warrant Shares since April 12, 2022, which will also result in the incurrence of Registration Delay Payments under the RRA. |
| E. | In order to facilitate the timely issuance of the Company audited financial statements for the year ended December 31, 2021, and to document by this Agreement that no Triggering Event under the COD has occurred prior to the date of this Agreement, and to confirm that a Triggering Event will occur under the COD on April 29, 2022, as described above unless the Investor agrees to a forbearance and waiver in accordance with the terms and conditions of this Agreement, the Parties desire to enter into this Agreement. |
NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledge, the Parties agree as follows:
1. Forbearance Payments. Upon the execution of this Agreement, the Company shall pay (x) the Investor, by wire transfer in immediately available funds, an aggregate amount, in U.S. dollars and immediately available funds, equal to Five Hundred Thirty Three Thousand Eight Hundred Twenty Three Dollars ($533,823.00) in satisfaction of all cash amounts due and payable under the Transaction Documents through March 31, 2022 and (y) the Legal Fee Amount (as defined below) to Kelley Drye & Warren LLP (collectively, the “Initial Forbearance Payments”). So long as the Registration Statement and the Prospectus contained therein remains unavailable to the Investor for the resale of the Required Registration Amount of Registrable Securities, the Company shall timely pay to the Investor the additional Registration Delay Payments of $400,000 as, and when, required pursuant to Section 2(e) of the RRA until the earlier to occur of such date in which (A) the Registration Statement and Prospectus is available to the Investor for the resale of the Required Registration Amount of Registrable Securities (the “Registration Statement Availability Date”) or (B) the Investor is permitted to resell the Registrable Securities without restrictions under and without the requirement for current public information under Rule 144(c)(1) (such date, the “144 Eligibility Date”, and such earlier date between the Registration Statement Availability Date and the 144 Eligibility Date, the “Resale Availability Date”).
2. Forbearance of Triggering Events under the COD. After the Company has paid the initial Forbearance Payments as set forth in, and in accordance with, Section 1 of this Agreement, until the earlier to occur of (i) the date immediately prior to the date of occurrence of a Bankruptcy Triggering Event, (ii) the date of occurrence of any other Triggering Event under Section 5(a) of the COD (excluding any Triggering Event arising solely as a result of Section 5(a)(ii) of the COD and Section 4(c)(ii) of the Warrant), (iii) the time of any breach by the Company pursuant to this Agreement, (iv) the Resale Availability Date and (v) June 4, 2022(such period, the “Forbearance Period”), the Investor agrees to forbear exercising any rights or remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a)(ii) of the COD and Section 4(c)(ii) of the Warrant.
3. Waiver of Triggering Events under the COD. Provided that the Company is not in breach of its obligations under this Agreement, effective as of the Trading Day immediately following the Resale Availability Date, the Investor agrees to waive any rights or remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a) of the COD and section 4(c)(ii) of the Warrant that may have arisen prior to the date of this Agreement. For the sake of clarity, if the Forbearance Period ends prior to the occurrence of the Resale Availability Date, the Investor shall maintain all of its rights and remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a)(ii) of the COD and Section 4(c)(ii) of the Warrant from and after the date of this Agreement.
4. Filing of the Post-Effective Amendment to the Registration Statement. During the Forbearance Period, the Company shall use its best efforts to file the post-effective amendment to the registration statement on or before April 29, 2022, or as soon as possible thereafter and to diligently perform all other obligations it may have under the RRA and shall not unduly delay or hinder the filing of the post-effective amendment.
5. Ratification. Except as specifically provided in this Agreement, all other terms and conditions of the COD, SPA and RRA remain in full force and effect.
6. Fees. The Company shall reimburse Kelley Drye & Warren LLP, on demand, for all costs and expenses incurred by it in connection with preparing and delivering this Agreement in an aggregate non-accountable amount equal to $5,000 (the “Legal Fee Amount”).
IN WITNESS WHEREOF, each of the Parties have caused their respective signature page to this Agreement to be duly executed as of the date first written above.
| COMPANY | |
|
Allarity Therapeutics, Inc a Delaware corporation | |
|
/s/ Steve Carchedi | |
| By: Steve Carchedi, CEO | |
| INVESTOR | |
|
3i, LP a Delaware limited partnership
/s/ Maier J. Tarlow | |
| By: Maier J. Tarlow | |
| Manager of the General Partner | |
Cover |
May 04, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | May 04, 2022 |
| Entity File Number | 001-41160 |
| Entity Registrant Name | ALLARITY THERAPEUTICS, INC. |
| Entity Central Index Key | 0001860657 |
| Entity Tax Identification Number | 87-2147982 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 210 Broadway |
| Entity Address, Address Line Two | Suite 201 |
| Entity Address, City or Town | Cambridge |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02139 |
| City Area Code | (401) |
| Local Phone Number | 426-4664 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share |
| Trading Symbol | ALLR |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G